Abstract
Experience Diagnosing, Understanding Care, and Treatment With Etanercept (EDUCATE) is a multicenter, phase 4, 24-week, open-label study of the safety and efficacy of etanercept therapy in patients with psoriatic arthritis (PsA) in routine dermatologic practice. We present data on patient-reported outcomes (PROs) from EDUCATE, which demonstrate that subjects with PsA achieved clinically meaningful improvements in both skin- and joint-related PROs after 24 weeks of treatment.
Publication types
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Arthritis, Psoriatic / drug therapy*
-
Etanercept
-
Female
-
Health Status
-
Humans
-
Immunoglobulin G / therapeutic use*
-
Immunologic Factors / therapeutic use*
-
Male
-
Middle Aged
-
Quality of Life
-
Randomized Controlled Trials as Topic
-
Receptors, Tumor Necrosis Factor / therapeutic use*
-
Recombinant Fusion Proteins / therapeutic use
-
Treatment Outcome
Substances
-
Immunoglobulin G
-
Immunologic Factors
-
Receptors, Tumor Necrosis Factor
-
Recombinant Fusion Proteins
-
Etanercept